Drug intelligence / Profile preview

EUROLIFE

Development stage: Preclinical
Lead developer: Semmelweis University
Modality: Small Molecules
Administration: Intravenous

Overview

EUROLIFE is a drug candidate developed by researchers at Semmelweis University, specifically within the context of the Eurolife network of European life sciences universities. It is being investigated for the treatment of acute pancreatitis, a condition characterized by sudden inflammation of the pancreas. While specific molecular details are often proprietary in early development, the drug is part of a broader research initiative at Semmelweis University aimed at identifying novel therapeutic interventions for pancreatic diseases. The development of EUROLIFE leverages the university's extensive expertise in gastroenterology and pancreatic research, focusing on mitigating the inflammatory response and preventing systemic complications associated with acute pancreatitis.

Brand names: EUROLIFE

Beyond the preview

Go deeper on EUROLIFE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EUROLIFE.

Explore the full profile